Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
September 09, 2021 12:46 ET
|
Clarus Therapeutics, Inc.; Blue Water Acquisition Corp.
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
July 15, 2021 09:00 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
December 07, 2020 09:00 ET
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
March 16, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
February 10, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019 14:04 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...
Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics’ JATENZO® Product: Trial Date Set for August 2020
August 26, 2019 08:30 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Clarus today announced that Lipocine, Inc. has confirmed that it will not seek preliminary injunctive relief against Clarus in a lawsuit that...
Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®
August 19, 2019 08:30 ET
|
Clarus Therapeutics, Inc.
JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal men and the first oral testosterone...
Clarus Therapeutics Refutes Patent Infringement Complaint
April 03, 2019 10:05 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., April 03, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that it will vigorously defend itself against an action brought by Lipocine, Inc. for patent...
Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men
March 27, 2019 16:27 ET
|
Clarus Therapeutics, Inc.
JATENZO is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men, and the first oral testosterone medicine...